Structure Therapeutics reported Phase 2 data showing its oral GLP‑1 agonist aleniglipron produced about 16% placebo‑adjusted weight loss at 44 weeks. The company plans to advance the candidate into Phase 3 later this year, positioning an oral alternative against injectable market leaders from Novo Nordisk and Eli Lilly. The trial randomized patients through dose escalations and reported tolerability improvements after changing the step‑up regimen; company statements and analyst notes framed the result as best‑in‑class for an oral GLP‑1 to date. GLP‑1 agonists mimic gut hormones that lower appetite and raise insulin secretion; oral formulations aim to match injectable efficacy while offering a pill option for patients.